Phase IB Randomized Study of the Selective Estrogen Receptor Modulators (SERMs) Tamoxifen and LY353381HCl, and Placebo, in Postmenopausal Women with Newly-Diagnosed Breast Cancer

Phase IB, NCI, Activated

Eligibility Requirements:

Disease Characteristics

Newly diagnosed breast cancer

Prior/Concurrent Therapy

Fourteen or more days between biopsy and lumpectomy or mastectomy

Patient Characteristics

Postmenopausal

Carol Fabian, M.D. is the Principal Investigator. Please contact Julie Anderson, (913) 588-3627 for more information or for patient registration.